Currently, many efforts are focusing on understanding the role of various cellular processes/pathways in PD and uncovering novel targets within these pathways for therapeutic development. As such, sensitive biomarker readouts for these pathways will be critical for bridging the gap from basic to translational research and clinical trials. The Parkinson’s Pathway Biomarkers program is open to industry and academic investigators proposing studies in aimed at (1) developing sensitive readouts for pathway activation/dysfunction and (2) improving technologies for analyzing the target/pathway of interest.
Applications should focus on studies in one or more of the following areas:
- Biomarker studies focusing on pathways that are known to be affected in PD (e.g.,inflammation, mitochondrial function, lysosomal function, autophagy, protein trafficking, protein handling).
- Studies developing novel pathway-based outcome measures or biochemical assays for PD.
- Studies optimizing existing assays to assess PD-related pathways or pathway-based targets.
- Studies investigating translational biomarkers that can be assessed in preclinical models as well as patient samples.
For more informations viste the webiste page: Parkinson’s Pathway Biomarkers
Awards: Up to $300,000
Deadline for pre-proposals: May 14, 2020
Full proposals (by invite only): September 22, 2020